SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001178913-23-002136
Filing Date
2023-06-05
Accepted
2023-06-05 07:00:22
Documents
16
Period of Report
2023-06-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2329839.htm   iXBRL 8-K 59129
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 18716
7 image00001.jpg GRAPHIC 32451
8 image00002.jpg GRAPHIC 21607
  Complete submission text file 0001178913-23-002136.txt   347174

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cmmb-20230601.xsd EX-101.SCH 4643
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmmb-20230601_def.xml EX-101.DEF 18313
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmmb-20230601_lab.xml EX-101.LAB 28539
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmmb-20230601_pre.xml EX-101.PRE 20555
10 EXTRACTED XBRL INSTANCE DOCUMENT zk2329839_htm.xml XML 6617
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38807 | Film No.: 23991199
SIC: 2834 Pharmaceutical Preparations